

### Antimicrobial Stewardship Lessons: Know When to Say No to Vancomycin

TO THE EDITOR—O'Horo et al [1] found that negative predictive value of Gram stain for the diagnosis of ventilator-associated pneumonia (VAP) was 91% (for a prevalence between 20% and 30%), suggesting that VAP is unlikely with a negative Gram stain result. Moreover, there was only a fair concordance between organisms on Gram stain and those recovered from culture. However, a remarkable result was the high accordance between Gram stain and culture results for gram-positive organisms. The impact of these later finding on the empirical therapy for gram-positive organisms is worth to be discussed.

Methicillin-resistant *Staphylococcus aureus* (MRSA) prevalence in VAP is quite variable. Several risk factors for MRSA infection are described, but local prevalence is a potential compelling factor for empirical coverage of this pathogen [2]. Episodes of VAP due to MRSA are associated with high rates of inappropriate therapy and worse outcomes [3], mainly when anti-MRSA

drugs are not included in empirical therapy. Despite that, strategies to spare exposure to anti-MRSA drugs such as vancomycin or linezolid could be useful to diminish selection pressure and resistance emergence in gram-positive pathogens [4].

We evaluated the accordance of Gram stain and the bacteria recovered from culture of respiratory tract specimens collected from critical patients at Hospital de Clínicas de Porto Alegre, an 845-bed university-affiliated tertiary care hospital located in Brazil. From May 2006 to December 2010 we prospectively evaluated 406 cases of microbiologic confirmed cases of VAP.

Three hundred seventy-six (92.6%) of 406 samples were obtained using endotracheal aspirate (cutoff for positivity of  $10^5$  colony-forming units [CFU]/mL), and 30 (7.4%) were obtained by bronchoalveolar lavage (cutoff for positivity of  $10^4$  CFU/mL). *Acinetobacter baumannii* was identified in 22.7% (n = 92), *S. aureus* in 18.0% (n = 73), *Pseudomonas aeruginosa* in 17.0% (n = 69), and *Klebsiella* species in 13.1% (n = 53) of patients.

For patients with gram-positive cocci in clusters (n = 63), 81.0% (n = 51) had *S. aureus* identified by culture results. In contrast, for those patients without gram-positive cocci in cluster, 6.7% (n = 22) had *S. aureus* identified by culture. Therefore, the presence of gram-positive clusters had a sensitivity of 69.8% (95% confidence interval [CI], 57.8–79.7); specificity of 96.2% (95% CI, 93.3–97.9); positive predictive value of 80.9% (95% CI, 68.7–89.3); and negative predictive value of 93.3% (95% CI, 89.8–85.6) for recovery of *S. aureus* on culture.

The incidence of MRSA in our intensive care unit has progressively fallen from 12.4 infections per 1000 patients-days in 2005, to 2.5 infections per 1000 patient-days in 2010. Of the 22 cases of *S. aureus* infection without gram-positive cocci in cluster identification, 15

were MRSA; of these, 5 were identified in 2006, 6 in 2007, 2 in 2008, 1 in 2009, and 1 in 2010.

Considering these results and those by O'Horo et al, together with the risk associated with vancomycin use (see step 7 of the Centers for Disease Control and Prevention's campaign to prevent antimicrobial resistance in healthcare settings, "Know when to say no to vanco" [5]), we suggest that clinicians reconsider the empirical use of anti-MRSA drugs in low-MRSA-prevalence settings when there is no evidence of gram-positive organisms in clusters on Gram stain of respiratory specimens.

## Notes

**Author contributions.** All authors contributed equally to this work.

**Potential conflicts of interest.** All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**Rodrigo Pires dos Santos,<sup>1</sup>  
Caroline Deuschendorf,<sup>1</sup> Fabiano Nagel,<sup>1,2</sup>  
Loriane Konkewicz,<sup>1</sup> and Thiago Lisboa<sup>1,2</sup>**

<sup>1</sup>Infection Control Committee and <sup>2</sup>Intensive Care Unit, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

## References

1. O'Horo JC, Thompson D, Safdar N. Is the Gram stain useful in the microbiologic diagnosis of VAP? A meta-analysis. *Clin Infect Dis* **2012**; 55:551–61.
2. Rello J, Ulldemolins M, Lisboa T, et al. Determinants of prescription and choice of empirical therapy for hospital acquired and ventilator-associated pneumonia. *Eur Respir J* **2011**; 37:1332–9.
3. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. *Clin Infect Dis* **2000**; 31(suppl 4):S131–8.

4. Clark NM, Hershberger E, Zervos MJ, Lynch JP 3rd. Antimicrobial resistance among gram-positive organisms in the intensive care unit. *Curr Opin Crit Care* **2003**; 9: 403–12.
5. CDC's campaign to prevent antimicrobial resistance in health-care settings. *MMWR Morb Mortal Wkly Rep* **2002**; 51: 343.

Correspondence: Rodrigo Pires dos Santos, MD, PhD, Infection Control Committee, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos 2350, Porto Alegre, 90035-003 RS, Brazil (rpsantos@hcpa.ufrgs.br).

**Clinical Infectious Diseases** 2013;56(4):616–7

© The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

DOI: 10.1093/cid/cis904